186 filings
8-K
MRKR
Marker Therapeutics Inc
25 Mar 24
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
6:18pm
8-K
MRKR
Marker Therapeutics Inc
1 Mar 24
Termination of a Material Definitive Agreement
8:02am
8-K
MRKR
Marker Therapeutics Inc
26 Feb 24
Entry into a Material Definitive Agreement
7:58am
8-K
MRKR
Marker Therapeutics Inc
8 Jan 24
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8:30am
8-K
MRKR
Marker Therapeutics Inc
11 Dec 23
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
7:35am
8-K
uffdd83 pkspn0t
20 Nov 23
Departure of Directors or Certain Officers
4:37pm
8-K
br1wtkgl
9 Nov 23
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
5:03pm
8-K
fkk9i bx9
11 Sep 23
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
7:10am
8-K
olb933zbgphd4ml8
14 Aug 23
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:37pm
8-K
bp8xjrxt73cvdc89nc
7 Aug 23
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
7:22am
8-K
py02snj 0u3
10 Jul 23
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
7:09am
8-K
j6j3o5 ze
3 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
7jtjmjtx6g1rbbxo
30 Jun 23
Completion of Acquisition or Disposition of Assets
4:05pm
8-K
xe6rq5sgdsp7g ai0kq
26 Jun 23
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
7:14am
8-K
c68loyp7a
12 Jun 23
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
7:09am
8-K
w5dlx62dhkrg36a
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
3auppbjqksyyrh6y
31 May 23
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
6:44am
8-K
vkwpr4bseje3 rh4lnb
8 May 23
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
7:45am
8-K
u7ctf8k535bcv4xc
1 May 23
MaRKER Announces LeADERSHIP TRANSITION & ProVIdes UPDATE ON OPERATIONAL STRATEGY
7:36am
8-K
s01jc8z6 wj
22 Mar 23
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
8:18am